Subscribe To
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Sutro biopharma announces presentation of data for luveltamab tazevibulin (luvelta) from the phase 1 dose-expansion study in endometrial cancers at esmo 2023
– Luvelta demonstrated encouraging preliminary anti-tumor activity (29% response rate) in late-stage patients with recurrent/relapsed endometrial ca...
October 22, 2023, 8:25 am
Olema oncology announces positive phase 2 monotherapy clinical study results for palazestrant
Across all 86 heavily pretreated patients, the median PFS was 4.6 months with a CBR of 40%; in patients with ESR1 mutations at baseline, the median PF...
October 22, 2023, 6:55 am
Beam: opportunity based on scd data readout in 2024
Beam Therapeutics is progressing well with its phase 1/2 BEACON study using BEAM-101 for severe sickle ...
October 22, 2023, 6:39 am
Revolution medicines presents promising clinical activity and safety data from phase 1/1b trial of rmc-6236
Investor Webcast to be held Sunday, October 22 at 12:30 p.m. Eastern Time REDWOOD CITY, Calif., Oct. 22, 2023 (GLOBE NEWSWIRE) — Revolution Medicine...
October 22, 2023, 6:30 am
Harpoon therapeutics announces updated interim tolerability and response data from phase 1/2 clinical trial of t cell engager hpn328 at esmo congress 2023
Confirmed response rate 35% (11/31), across all tumor types and patient cohorts treated with 1 mg priming dose, including three confirmed, complete re...
October 21, 2023, 3:31 pm
Libtayo® (cemiplimab) neoadjuvant treatment demonstrates encouraging event-free survival in patients with resectable cutaneous squamous cell carcinoma (cscc)
89% estimated event-free survival at one year among patients with stage II to IV resectable CSCC who received Libtayo prior to surgery in a ...
October 21, 2023, 12:48 pm
Initial phase 1 dose escalation data of oric-114 in patients with egfr and her2 exon 20 mutations demonstrates potential best-in-class profile
CNS activity observed at multiple dose levels, including the first reported confirmed CNS complete response by an EGFR exon 20 inhibitor in a patient ...
October 21, 2023, 11:30 am
Bofa: crowded usd longs signal caution; convergence with rate differentials underway
Synopsis: BofA highlights a potential market saturation with USD long positions, as evidenced by the currency's understated response to positive US re...
October 20, 2023, 2:06 pm
Will solar stocks be the next big short squeeze?
Solar stocks are taking a massive hit today following lowered guidance and a bleak warning from SolarEdge (NASDAQ: SEDG ). These factors are bringing ...
October 20, 2023, 1:19 pm
Eli lilly planning diabetes drug trial for children six years and older: report
Eli Lilly and Co (NYSE:LLY) is planning a trial of its diabetes drug Mounjaro in patients with obesity as young as six years old according to a Bloomb...
October 20, 2023, 1:01 pm
: merck’s keytruda shows positive results in confirmatory trial as treatment for rare form of esophageal cancer
Merck & Co. MRK said Friday a late-stage trial of its blockbuster cancer drug Keytruda plus trastuzumab, fluoropyrimidine- and platinum-containing che...
October 20, 2023, 12:13 pm
Why enphase energy shares plunged friday
Higher interest rates in the U.S. have been a headwind. Enphase stock has already plunged by 50% in the...
October 20, 2023, 10:49 am
Bp in talks to exit senegal's yakaar-teranga natural gas field
BP-operated Yakaar-Teranga phase 1 represents a conventional gas development in the ultra-deepwater reg...
October 20, 2023, 9:46 am
What friday's plunges in solaredge, enphase say about growth stocks
Markets were poised to fall again on Friday. SolarEdge shares plunged on warnings about third-quarter results and expectations for the rest of 2023....
October 20, 2023, 9:24 am
Gold price tops near major resistance after fed speech
XAU/USD is strongly bullish after failing to retest the uptrend line. A new lower low activates a corrective phase. The Canadian retail sales could mo...
October 20, 2023, 9:22 am